Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics Inc | RCV000711121 | SCV000841449 | uncertain significance | not provided | 2018-03-27 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000796351 | SCV000935861 | benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2023-10-10 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001269149 | SCV001448413 | uncertain significance | not specified | 2020-11-04 | criteria provided, single submitter | clinical testing | Variant summary: CACNA1H c.6023G>T (p.Ser2008Ile) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 9.5e-05 in 147894 control chromosomes (gnomAD). To our knowledge, no occurrence of c.6023G>T in individuals affected with CACNA1H-Related Disorders and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and both of them classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |